Clusterin in stool: A new biomarker for colon cancer screening?

American Journal of Gastroenterology

Volumn 104, Issue 11, 2009, Pages 2807-2815

  Pucci, Sabina ^a   Bonanno, Elena ^a   Sesti, Fabiola ^a   Mazzarelli, Paola ^a   Mauriello, Alessandro ^a   Ricci, Federico ^a   Zoccai, Giuseppe Biondi ^b   Rulli, Francesco ^a   Galatà, Gabriele ^a   Spagnoli, Luigi G ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CLUSTERIN; MOLECULAR MARKER; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CANCER SIZE; CLINICAL FEATURE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DOT HYBRIDIZATION; ENTERITIS; FECES ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; XENOGRAFT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANIMALS; BIOPSY, NEEDLE; BLOTTING, WESTERN; CLUSTERIN; COLONIC NEOPLASMS; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PILOT PROJECTS; PROBABILITY; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 72049131833     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.412     Document Type: Article

References (22)

1. Levin B, Lieberman DA, McFarland B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008 ; 58 : 130-60.
2. Walsh JME. Colorectal cancer screening. JAMA 2003 ; 289 : 1288-96.
3. Burch JA, Soares-Weiser K, St John DJB et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen 2007 ; 14 : 132-7.
4. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale: update based on new evidence. Gastroenterology 2003 ; 124 : 544-60.
5. Winawer SJ. The multidisciplinary management of gastrointestinal cancer. Colorectal cancer screening. Best Pract Res Clin Gastroenterol 2007 ; 21 : 1031-48.
6. Ouyang DL, Chen JJ, Getzenberg RH et al. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol 2005 ; 100 : 1393-403.
7. Pucci S, Bonanno E, Pichiorri F et al. Modulation of diff erent clusterin isoforms in human colon tumorigenesis. Oncogene 2004 ; 23 : 2298-304.
8. Redondo M, Villar E, Torres-Muñoz J et al. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000 ; 157 : 393-9.
9. Leskov KS, Klokov DY, Li J et al. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003 ; 278 : 11590-600.
10. Yang CR, Leskov K, Hosley-Eberlein K et al. Nuclear clusterin/XIP8, an X-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 2000 ; 97 : 5907-12.
11. Pucci S, Bonanno E, Pichiorri F et al. The expression and the nuclear activity of the caretaker gene ku86 are modulated by somatostatin. Eur J Histochem 2004 ; 48 : 103-10.
12. Pucci S, Mazzarelli P, Sesti F et al. Interleukin-6 aff ects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression. Cell Cycle 2009 ; 8 : 1-9.
13. Trougakos IP, Poulakou M, Stathatos M et al. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol 2002 ; 37 : 1175-87.
14. Morrissey C, Lakins J, Moquin A et al. An antigen capture assay for the measurement of serum clusterin concentrations. J Biochem Biophys Methods 2001 ; 48 : 13-21.
15. Stejskal D, Fiala RR. Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma 2006 ; 53 : 343-6.
16. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Pediatrica 2007 ; 96 : 644-7.
17. Vergara IA, Norambuena T, Ferrada E et al. StAR: a simple tool for the statistical comparison of ROC curves. BMC Bioinformatics 2008 ; 9 : 265.
18. Jankowski JA, Odze RD. Biomarkers in gastroenterology: between hope and hype comes histopathology. Am J Gastroenterol 2009 ; 104 : 1093-6.
19. Bonanno E, Rulli F, Galatà G et al. Stool test for colorectal cancer screening: what is going on? Surg Oncol 2007 ; 16 : S43-5.
20. Tibble J, Sigthorsson G, Foster R et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001 ; 49 : 402-8.
21. Lemn ES, Shoen RE, Magheli A et al. Evaluation of cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res 2008 ; 14 : 1349-54.
22. Giuttet L, Bouvier V, Vallee JP et al. Comparison of guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007;56 : 210-21.